![DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes](https://oncodaily.com/pub/uploads/2024/09/abmVCNwyRRoFk9gcFke1-e1725420181257.png)
Sep 6, 2024, 11:26
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes
International Urology Cancer Summit made the following post on X:
“Non-BRCA1/2 HRR mutations might benefit from PARP inhibitors when direct BRCA complex interaction. Intriguing the effectiveness of platinum across all cohorts.”
Authors: Laura S. Graham, MD, Nicholas C. Henderson, Olesia Kellezi, BS, Clara Hwang, MD, Pedro C. Barata, MD, Mehmet A. Bilen, MD, Deepak Kilari, MD, Michael Pierro, MD, Bicky Thapa, MD, Abhishek Tripathi, MD, George Mo, MD, Matthew Labriola, MD, Joseph J. Park, MD, Shoshana Rothstein, MD, Rohan Garje, MD, Vadim S. Koshkin, MD, Vaibhav G. Patel, MD, Tanya Dorff, MD, Andrew J. Armstrong, MD, Rana R. McKay, MD, Ajjai Alva, MD and Michael T. Schweizer, MD
Abhishek Tripathi
Ajjai Alva
Andrew J. Armstrong
Bicky Thapa
BRCA mutations
cancer
Clara Hwang
Deepak Kilari
DNA-damaging therapies
George Mo
homologous recombination repair genes
Joseph J. Park
Laura S. Graham
Matthew Labriola
Mehmet A Bilen
Michael Pierro
Michael T Schweizer
Nicholas C. Henderson
Olesia Kellezi
OncoDaily
Oncology
PARP inhibitors
Pedro C Barata
platinum-based therapy
prostate cancer
Rana R. McKay
Rohan Garje
Shoshana Rothstein
Tanya Dorff
Vadim S Koshkin
Vaibhav G. Patel
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023